Browse Conditions Browse Medicines

NICE encourages use of greener asthma inhalers

Aerivio Spiromax , for Asthma and Asthma (eosinophilic) from Teva UK Limited

The National Institute for Health and Care Excellence (NICE) is encouraging asthma patients on using greener asthma inhalers.

NICE highlight a new patient decision aid indicating which inhalers have a higher carbon footprint than others.

The aid will help people with asthma, alongside health professionals, to identify which inhalers could meet their needs and control their symptoms.

Where several inhalers could be viable options, patients can opt for the more environmentally friendly option, which may help to cut the health service’s carbon footprint.

The new aid, partially funded by the Sustainable Development Unit, also says that all used inhalers should be returned to local pharmacies for environmentally safe disposal or recycling.

The National Institute for Health and Care Excellence (NICE) says everyone should be able to choose the inhaler they find easiest to use. NICE also says that everyone should have the way they use their inhaler checked regularly. If needed, people should be given advice on how to improve their technique

The Patient Decision Aid covers the following inhaler options.

Inhaler type Examples
Breath-actuated metered dose
inhaler (BAI)
Dry powder
inhaler (DPI)
metered dose inhaler (pMDI)
plus a spacer
AeroChamber Plus
A2A spacer
Able Spacer
Antistatic Space Chamber Plus devices
OptiChamber Diamond
Pocket Chamber
Space Chamber Plus devices
Soft mist inhaler (SMI) These have not been included in the patient
decision aid as they are not an option for many people
Your healthcare professional will be able to advise you if it is an option for you. They will explain to you how it works.

© NICE [2019]

Patient decision aid. Inhalers for asthma
Available from: See Link below. All rights reserved. Subject to Notice of rights
NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

The information provided by NICE was accurate at the time this article was issued.

NICE Patient Decision Aid on 'green' inhalers

Reporting of suspected adverse reactions

Reporting suspected adverse reactions (side effects) after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals or patients are asked to report any suspected adverse reactions via the Yellow Card Scheme at or search for MHRA Yellow Card in the Google Play or Apple App Store.

Disclaimer: This site is designed to offer information for general educational purposes only. The health information furnished on this site and the interactive responses are not intended to be professional advice and are not intended to replace personal consultation with a qualified physician, pharmacist, or other healthcare professional. We cannot provide individual medical advice. You must always seek the advice of a professional for questions related to a disease, disease symptoms, and appropriate therapeutic treatments.

About Asthma About Asthma (eosinophilic) About medicine